Literature DB >> 31103632

Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in rats.

Tyler C Beck1, Carmela M Reichel2, Kristi L Helke3, Sanat S Bhadsavle1, Thomas A Dix4.   

Abstract

Addiction to conventional opioid pain analgesics is a major societal problem that is increasing at an alarming rate. New drugs to combat the effects of opioid abuse are desperately needed. Kappa-opioid agonists are efficacious in peripheral pain models but suffer from centrally-mediated effects. In this article, we discuss our efforts in developing peripheral kappa-based opioid receptor agonists that have the potential analgesic activity of opioids but do not manifest the negative side-effects of opioid use and abuse. Further, derivatives of the tetra-peptide D-Phe-D-Phe-D-Nle-D-Arg-NH2, such as CR665, exhibit high peripheral to central selectivity in analgesic models when administered intravenously (i.v.); however, they are inactive when administered orally. Application of our laboratory's proprietary non-natural amino acid technology to CR665 produced derivatives that exhibit peripheral analgesic activity when dosed orally but do not promote CNS-based effects. Lead compound JT09 activates the kappa-opioid receptor with EC50s in the low nM range, while agonist selectivity for kappa over other peripheral opioid receptors was >33,400 fold. Results indicate that JT09 is approximately as efficacious as morphine in alleviating peripheral pain, while failing to produce undesired CNS-mediated activity. Additionally, JT09 did not promote other CNS-mediated effects associated with morphine (addiction, sedation, dysphoria, tolerance, addiction). Thus, we propose that JT09 has potential for development as a novel analgesic. PERSPECTIVE: This article presents data supporting the analgesic properties of an orally available, peripherally-restricted, kappa-opioid agonist for peripheral pain. A potential out-patient pharmaceutical that acts as efficacious as morphine in alleviating peripheral pain, while failing to produce undesired CNS-mediated effects, could help reduce the current health care burden associated with prescription opioids. Crown
Copyright © 2019. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Analgesic; Kappa; Opioid; Pain; Peripheral

Mesh:

Substances:

Year:  2019        PMID: 31103632      PMCID: PMC6696947          DOI: 10.1016/j.ejphar.2019.05.025

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via μ- and κ-opioid receptors.

Authors:  Biao Xu; Mengna Zhang; Xuerui Shi; Run Zhang; Dan Chen; Yong Chen; Zilong Wang; Yu Qiu; Ting Zhang; Kangtai Xu; Xiaoyu Zhang; Wolfgang Liedtke; Rui Wang; Quan Fang
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

2.  Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics.

Authors:  Jacob K Meariman; Jane C Sutphen; Juan Gao; Daniel R Kapusta
Journal:  Hypertension       Date:  2021-12-02       Impact factor: 10.190

Review 3.  The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies.

Authors:  Martin L Dalefield; Brittany Scouller; Rabia Bibi; Bronwyn M Kivell
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

Review 4.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

5.  Targeting peripheral ϰ-opioid receptors for the non-addictive treatment of pain.

Authors:  Tyler C Beck; Thomas A Dix
Journal:  Future Drug Discov       Date:  2019-09-02

Review 6.  The Role of the Kappa Opioid System in Comorbid Pain and Psychiatric Disorders: Function and Implications.

Authors:  Miao-Jin Ji; Jiao Yang; Zhi-Qiang Gao; Liang Zhang; Chao Liu
Journal:  Front Neurosci       Date:  2021-02-24       Impact factor: 4.677

7.  Diuretic Activity of a Novel Peripherally-Restricted Orally-Active Kappa Opioid Receptor Agonist.

Authors:  Tyler C Beck; Matthew A Hapstack; Gautam S Ghatnekar; Thomas A Dix
Journal:  Med Sci (Basel)       Date:  2019-08-31

8.  Evaluation of Antinociceptive Effects of Chitosan-Coated Liposomes Entrapping the Selective Kappa Opioid Receptor Agonist U50,488 in Mice.

Authors:  Liliana Mititelu Tartau; Maria Bogdan; Beatrice Rozalina Buca; Ana Maria Pauna; Cosmin Gabriel Tartau; Lorena Anda Dijmarescu; Eliza Gratiela Popa
Journal:  Medicina (Kaunas)       Date:  2021-02-04       Impact factor: 2.430

9.  Exploring the neurobiology of the premonitory phase of migraine preclinically - a role for hypothalamic kappa opioid receptors?

Authors:  Caroline M Kopruszinski; Robson Vizin; Moe Watanabe; Ashley L Martinez; Luiz Henrique Moreira de Souza; David W Dodick; Frank Porreca; Edita Navratilova
Journal:  J Headache Pain       Date:  2022-09-30       Impact factor: 8.588

10.  Modulation of Hedgehog Signaling by Kappa Opioids to Attenuate Osteoarthritis.

Authors:  Alexander E Weber; Omid Jalali; Sean Limfat; Ruzanna Shkhyan; Robert Van Der Horst; Siyoung Lee; Yucheng Lin; Liangliang Li; Erik N Mayer; Liming Wang; Nancy Q Liu; Frank A Petrigliano; Jay R Lieberman; Denis Evseenko
Journal:  Arthritis Rheumatol       Date:  2020-06-24       Impact factor: 10.995

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.